Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-030988
Filing Date
2024-08-09
Accepted
2024-08-09 16:20:54
Documents
77
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1304476
2 ex31.htm EX-31 37055
3 ex32.htm EX-32 9340
  Complete submission text file 0001493152-24-030988.txt   7584587

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ser-20240630.xsd EX-101.SCH 50212
5 XBRL CALCULATION FILE ser-20240630_cal.xml EX-101.CAL 71747
6 XBRL DEFINITION FILE ser-20240630_def.xml EX-101.DEF 248419
7 XBRL LABEL FILE ser-20240630_lab.xml EX-101.LAB 470318
8 XBRL PRESENTATION FILE ser-20240630_pre.xml EX-101.PRE 402471
80 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1204849
Mailing Address 601 GENOME WAY SUITE 2001 HUNTSVILLE AL 35806
Business Address 601 GENOME WAY SUITE 2001 HUNTSVILLE AL 35806 (256) 327-9630
Serina Therapeutics, Inc. (Filer) CIK: 0001708599 (see all company filings)

EIN.: 821436829 | State of Incorp.: AL | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38519 | Film No.: 241193111
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)